Adc Therapeutics Sa Stock Today
| ADCT Stock | USD 3.38 0.10 2.87% |
PerformanceFair
| Odds Of DistressHigh
|
ADC Therapeutics is selling for under 3.38 as of the 23rd of September 2025; that is 2.87% down since the beginning of the trading day. The stock's last reported lowest price was 3.38. ADC Therapeutics has more than 66 % chance of experiencing financial distress in the next few years of operation. It also did not have a very good performance during the last 90 trading days. The performance scores are derived for the period starting the 25th of June 2025 and ending today, the 23rd of September 2025. Click here to learn more.
ADC Therapeutics SA, a commercial-stage biotechnology company, develops antibody drug conjugates for patients suffering from hematological malignancies and solid tumors. ADC Therapeutics SA was incorporated in 2011 and is headquartered in Epalinges, Switzerland. The company has 112.5 M outstanding shares of which 4.14 M shares are presently shorted by private and institutional investors with about 5.69 trading days to cover. More on ADC Therapeutics SA
Moving against ADC Stock
Follow Valuation Odds of Bankruptcy
Check how we calculate scores
ADC Stock Highlights
ADC Therapeutics SA (ADCT) is traded on New York Stock Exchange in USA. It is located in BiopOle, Epalinges, Switzerland, 1066 and employs 263 people. ADC Therapeutics is listed under Communications Equipment category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a current market capitalization of 391.5 M. ADC Therapeutics conducts business under Communications Equipment sector and is part of Information Technology industry. The entity has 112.5 M outstanding shares of which 4.14 M shares are presently shorted by private and institutional investors with about 5.69 trading days to cover.
ADC Therapeutics SA currently holds about 376.78 M in cash with (123.83 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 4.9, which can makes it an attractive takeover target, given it will continue generating positive cash flow.
Check ADC Therapeutics Probability Of Bankruptcy
Ownership AllocationADC Therapeutics secures a total of 112.5 Million outstanding shares. Over half of ADC Therapeutics' outstanding shares are owned by institutions. These institutions are typically referred to as corporate investors that acquire positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company retains, if the real value of the firm is less than the current market value, you may not be able to make money on it.
Check ADC Ownership Details
ADC Therapeutics Risk Profiles
Investors will always prefer to have the highest possible return on investment while minimizing volatility. ADC Therapeutics market risk premium is the additional return an investor will receive from holding ADC Therapeutics long position in a well-diversified portfolio.
| Risk Adjusted Performance | 0.0741 | |||
| Jensen Alpha | 0.1226 | |||
| Total Risk Alpha | (0.41) | |||
| Sortino Ratio | 0.0652 |
ADC Stock Against Markets
ADC Therapeutics Corporate Directors
| Viviane Monges | Non-Executive Independent Director | Profile | |
| Thomas Pfisterer | Non-Executive Independent Director | Profile | |
| Tyrell Rivers | Non-Executive Independent Director | Profile | |
| Peter Hug | Non-Executive Independent Director | Profile |
Already Invested in ADC Therapeutics SA?
The danger of trading ADC Therapeutics SA is mainly related to its market volatility and Company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of ADC Therapeutics is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than ADC Therapeutics. The Sharpe ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile ADC Therapeutics is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Additional Tools for ADC Stock Analysis
When running ADC Therapeutics' price analysis, check to measure ADC Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ADC Therapeutics is operating at the current time. Most of ADC Therapeutics' value examination focuses on studying past and present price action to predict the probability of ADC Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ADC Therapeutics' price. Additionally, you may evaluate how the addition of ADC Therapeutics to your portfolios can decrease your overall portfolio volatility.